Weis Markets Reports Second Quarter 2026 Results

Weis Markets posts higher sales but quarterly profit slips amid pharmacy headwinds.

What the company is saying

Weis Markets, Inc. reports a 4.6% year-over-year increase in total revenue for the second quarter of 2026, reaching $1.28 billion. The company highlights a 2.3% rise in comparable store sales and emphasizes continued investment in promotions and loyalty marketing to drive customer engagement. Management acknowledges a $10.71 million negative impact on pharmacy revenue due to new Medicare pricing provisions under the Inflation Reduction Act. The announcement frames sales growth at newer stores as evidence of successful customer response, though no supporting data is provided. Net income for the quarter fell 9.6% to $22.86 million, but year-to-date net income rose 13.1% to $50.71 million. The Board declared a $0.34 per share quarterly dividend, reinforcing a message of ongoing shareholder returns. The tone remains neutral and factual, with limited qualitative commentary and no forward-looking guidance.

What the data suggests

Headline financials show total revenue up 4.6% year-over-year for both the quarter ($1.28 billion) and year-to-date ($2.53 billion), indicating steady top-line growth. Comparable store sales increased 2.3% for the quarter and 2.2% year-to-date, with two-year stacked gains of 4.1% and 3.6% respectively. Pharmacy revenue was hit by $10.71 million in the quarter and $18.19 million year-to-date due to Medicare pricing changes, directly impacting profitability. Second quarter net income declined 9.6% to $22.86 million, with earnings per share dropping to $0.92 from $0.96. In contrast, year-to-date net income rose 13.1% to $50.71 million, and EPS increased to $2.05 from $1.69, suggesting first quarter strength offset the recent dip. Gross profit for the quarter was $328.4 million on $946.9 million in cost of sales, with operating expenses at $299.3 million. The dividend of $0.34 per share is consistent with the company’s stated policy. No segment, geographic, or promotional spend breakdowns are disclosed, and there is no forward-looking guidance.

Analysis

The announcement is a standard quarterly earnings release, presenting realised financial results for the second quarter and year-to-date 2026. All key claims are supported by disclosed numerical data, including revenue, net income, comparable store sales, and dividend declaration. There are no forward-looking projections, aspirational statements, or exaggerated claims about future performance. The language is factual and restrained, with only minor qualitative statements about investments in promotions and customer response, which are not materially hyped and do not dominate the narrative. No large capital outlays or long-term benefit projections are disclosed. The gap between narrative and evidence is minimal, and the tone is proportionate to the results.

Risk flags

• ●Profitability risk is evident as second quarter net income declined by 9.6% despite revenue growth, indicating margin pressure or rising costs. This matters because sustained margin compression could erode future earnings even if sales continue to rise.
• ●Pharmacy segment vulnerability is highlighted by a $10.71 million quarterly and $18.19 million year-to-date revenue hit from Medicare pricing changes. Regulatory headwinds in this area could persist or worsen, affecting overall profitability.
• ●Disclosure risk exists due to the lack of granular data on segment performance, promotional spend, or geographic trends. Without this detail, investors cannot fully assess the sustainability or drivers of reported growth.

Bottom line

Weis Markets delivered higher sales and a modest increase in year-to-date profit, but quarterly net income fell as pharmacy headwinds and cost pressures weighed on margins. The company’s narrative of promotional investment and customer response is not backed by detailed data, and no forward-looking guidance or segment breakdowns are provided. The $0.34 per share dividend continues, but the lack of transparency on operational drivers limits visibility into future performance. For investors, the most important takeaway is that while top-line growth remains steady, margin and regulatory risks are rising, and the absence of detailed disclosures makes it difficult to gauge the durability of recent gains. Further clarity on segment profitability and cost structure would be needed to shift this assessment.

Announcement summary

(NYSE: WMK) Weis Markets, Inc. reported total revenue of $1.28 billion for the 13-week second quarter ended June 27, 2026, compared to $1.22 billion for the same period in 2025, a 4.6% increase. Second quarter comparable store sales increased 2.3% on an individual year-over-year basis and 4.1% on a two-year stacked basis. Pharmacy revenue growth was unfavorably impacted by approximately $10.71 million from pricing headwinds related to the Inflation Reduction Act Medicare maximum fair price provisions, effective January 1, 2026. The Company's second quarter net income was $22.86 million compared to $25.28 million in 2025, a 9.6% decrease, with earnings per share of $0.92 versus $0.96 in 2025. Year-to-date total revenue was $2.53 billion, up from $2.42 billion in 2025, a 4.6% increase, and year-to-date net income totaled $50.71 million compared to $44.83 million in 2025, a 13.1% increase. The Board of Directors declared a quarterly cash dividend of $0.34 per share to shareholders of record as of July 27, 2026, payable on August 10, 2026. Weis Markets currently operates 202 stores.

Disagree with this article?